This article was originally published in The Gray Sheet
Patent litigation settlement agreement announced July 12 calls for Vascular Solutions, Inc. to pay St. Jude 2.5% royalty on sales of its Duett femoral artery closure device in exchange for a non-exclusive license to St. Jude's "Fowler" patents related to sealing devices. The pact also provides for a non-exclusive cross license to VSI's "Gershony" patents if needed by St. Jude, which markets the Angio-Seal femoral artery closure device
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.